130 results on '"Vekeman, F."'
Search Results
2. COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING: CN4
3. Very Low Compliance for Vulvovaginal Atrophy (VVA) Treatment: A Retrospective U.S. Healthcare Claims Database Analysis
4. ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A RETROSPECTIVE CHART REVIEW STUDY AT THREE LARGE TERTIARY ONCOLOGY CENTERS IN THE UNITED STATES
5. MAINTENANCE OF WEIGHT LOSS OR STABLE WEIGHT IN SUBJECTS WITH OBESITY: A RETROSPECTIVE LONGITUDINAL ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA
6. A Life-Course Assessment Of Medication Use And Medical Costs Of Lennox-Gastaut Syndrome (Lgs)
7. Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
8. Adherence to Iron Chelation Therapy and associated Healthcare resource Utilization and costs in Medicaid Patients with Thalassemia
9. Kidney involvement in Tuberous Sclerosis Complex: the impact on Health Care resource use and costs in the Netherlands
10. Overall survival in post-menopausal women with hr+/her2- metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy
11. PIH32 - Very Low Compliance for Vulvovaginal Atrophy (VVA) Treatment: A Retrospective U.S. Healthcare Claims Database Analysis
12. Medical Complications And Resource Utilization In Blood Transfusion–Dependent Patients With Myelofibrosis By Iron Chelation Therapy Use
13. High Utilizers Of Health Care Resources: Results From The Multicenter Compact Study Of Complications In Patients With Sickle Cell Disease And Utilization Of Iron Chelation Therapy
14. High Cost Patients And Cost Patterns From Pediatric To Adult Care In A Medicaid Population With Sickle Cell Disease
15. PCN33 - Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
16. PSY11 - MAINTENANCE OF WEIGHT LOSS OR STABLE WEIGHT IN SUBJECTS WITH OBESITY: A RETROSPECTIVE LONGITUDINAL ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA
17. PSY24 - ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A RETROSPECTIVE CHART REVIEW STUDY AT THREE LARGE TERTIARY ONCOLOGY CENTERS IN THE UNITED STATES
18. PND51 - A Life-Course Assessment Of Medication Use And Medical Costs Of Lennox-Gastaut Syndrome (Lgs)
19. Pulse Pressure and Stroke Risk: Development and Validation of a Stroke Risk Equation
20. Health Care Resource Use and Direct Costs Associated with Fragile X Syndrome (FXS) in the United States
21. Development and validation of a new chronic kidney disease risk equation: the role of pulse pressure
22. Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD)
23. Incremental Cost Of Brain Metastases Among Patients With Metastatic Melanoma
24. Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders
25. Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the United States
26. PCV14 Are Vasodilators of Value in the Care of Patients Hospitalized for Acute Heart Failure?
27. PSY64 Development and Validation of a Classification Algorithm for Prophylactic Versus on-Demand Factor VIII Therapy in Patients With Hemophilia A
28. PCN2 SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED KINGDOM: PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY
29. PSY43 - Kidney involvement in Tuberous Sclerosis Complex: the impact on Health Care resource use and costs in the Netherlands
30. PSY27 - Adherence to Iron Chelation Therapy and associated Healthcare resource Utilization and costs in Medicaid Patients with Thalassemia
31. PCN31 - Overall survival in post-menopausal women with hr+/her2- metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy
32. PCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB
33. PUK28 ASSESSMENT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT GUIDELINES CHANGES ON DOSING PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
34. PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
35. PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
36. PSY35 PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE (SCD)
37. PCN19 BUDGET IMPACT ANALYSIS OF SARGRAMOSTIM USE IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA
38. PCN98 IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS
39. CN1 RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING
40. PCN25 DRUG UTILIZATION AND COSTS FOR ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN PATIENTS WITH BREAST, LUNG, OR GASTROINTESTINAL CANCER RECEIVING CHEMOTHERAPY
41. PCN8 COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
42. PND37 ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMER'S DISEASE TREATED WITH RIVASTIGMINE VERSUS DONEPEZIL: EVIDENCE FROM HEALTH CLAIMS DATA
43. DU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
44. PND20 COMPLIANCE AND PERSISTENCE OF ORAL CHOLINESTERASE INHIBITORS IN PATIENTS WITH ALZHEIMER'S DISEASE
45. PCN26 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY
46. PCN86 DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
47. PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY
48. PCN25 REAL-WORLD EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) DOSING AND COST CONSIDERATIONS IN ELDERLY HOSPITAL INPATIENTS: RESULTS FROM A LARGE OBSERVATIONAL STUDY
49. PCN17 MEDICAL COST CONSIDERATIONS OF FIXED DOSING REGIMENS OF ERYTHROPOIETIC AGENTS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA
50. CN4 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.